Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens
Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its LiveDesign software, giving biotech teams direct access to Lilly’s predictive models. Revvity and Benchling also announced deals to offer TuneLab through their platforms. Lilly and Revvity will jointly fund access for select users, using federated learning to protect data. BigHat Biosciences will collaborate with Lilly to improve antibody developability models.
